FDA Issues New Guidance on Assessing REMS

Drug GMP Report
A A
The FDA released two draft guidances outlining the agency’s latest thinking on assessments of risk evaluation and mitigation strategy (REMS) programs.

To View This Article:

Login

Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $40.00